

Patient Name : Mrs. J A SUNETHRA PERERA	Collected : 31/Dec/2024 04:45PM
Age/Gender : 76 Years/F	Received : 31/Dec/2024 05:19PM
UHID/MR No : AEKR.0000097394	Reported : 08/Jan/2025 10:05AM
TRID : TRID-2024-05063	Status : Final Report
Ref By : Dr. SUJEEWA SIYAMBALAPITIYA	
IP/OP NO :	

CYTOGENETICS REPORT

Fluorescence In Situ Hybridization (FISH) For Her 2/Neu Gene Amplification , FFPE Block

ID	TR-FI-HER2-338-24
Specimen Identification	FFPE block with breast tissue, No. 655/W/23 (F4654)
Test done on	FFPE block with breast tissue, No. 655/W/23 (F4654)
Clinical Indication	Grade III Invasive ductal Carcinoma
Test	HER2 Amplification detection by FISH
Probe	HER2 (17q12) and chromosome 17 centromere (D17Z1) Control probe (MetaSystems)
Method	Dual Color FISH using XL ERBB2 (HER2/NEU) Amplification probe

ANALYSIS

Number of cells counted	60
Total HER2 signals	127
Avg HER2 signals / cell	2.11
Total CEP-17 signals	119
Avg CEP-17 signals/cell	1.98
HER2/CEP-17 ratio	1.06
Result	HER2 test result is Negative

Comments : Her-2/neu gene is not amplified.

***Interpretation**

Positive based on
 HER2/CEP17 ratio ≥ 2.0 with an average HER2 copy number ≥ 4.0 signals per cell
 HER2/CEP17 ratio ≥ 2.0 with an average HER2 copy number < 4.0 signals/cell
 HER2/CEP17 ratio < 2.0 with an average HER2 copy number ≥ 6.0 signals/cell
 Equivocal based on
 HER2/CEP17 ratio < 2.0 with an average HER2 copy number ≥ 4.0 and < 6.0 signals/cell

Patient Name : Mrs. J A SUNETHRA PERERA	Collected : 31/Dec/2024 04:45PM
Age/Gender : 76 Years/F	Received : 31/Dec/2024 05:19PM
UHID/MR No : AEKR.0000097394	Reported : 08/Jan/2025 10:05AM
TRID : TRID-2024-05063	Status : Final Report
Ref By : Dr. SUJEEWA SIYAMBALAPITTIYA	
IP/OP NO :	

CYTOGENETICS REPORT

Negative based on
 HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals/cell

***Ref**


Wolff, A., et al. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36(20), pp.2105-2122.

Note : For FFPE blocks received from outside, fixation details not available.

Disclaimer

1. This test is intended as an adjunct to existing prognostic clinical and pathologic information for breast and gastric cancer patients. It is not intended to diagnose or screen for breast or gastric cancer. Since only a portion of the tumor was tested, it is possible that this result may not represent the entire tumor population.
2. As per ASCO/CAP guidelines, HER2 FISH test results are valid for non-decalcified paraffin embedded specimens fixed in 10% neutral buffered formalin between 6 and 48 hours. Results from specimens fixed outside these parameters should be interpreted accordingly.
3. The said report is strictly not a medical/medical laboratory/diagnostic report and/or an opinion with regard to test results. The authorised signatories are only responsible for signing Technical report/Test report i.e a report stating the test results and the processes, if any, indicating the analysis of sample without recording any medical opinion or diagnosis of any medical condition.

3 Blocks & 3 Slides enclosed



***** End Of Report *****

Entered By :

Miss. Nissi Daniel
 Trainee-Scientific Officer

Verified By:

Dr Gautam Balaram
 KMC No.: 93340
 MD Pathology

Approved By :

Dr. Akhila Raj T V, Ph.D.
 Senior Scientist I, Cytogenetics
 & FISH